Foundayo's first week brings 1,390 prescriptions as Lilly's oral obesity pill reaches market

Eli Lilly's oral obesity pill Foundayo (orforglipron) was prescribed 1,390 times in the United States in its first week on sale, according to IQVIA data cited by analysts ^[1][2]. It is the first hard sales figure for the once-daily tablet, which Lilly has positioned as a more convenient alternative to injected GLP-1 medicines ^[2].

Foundayo was approved in the U.S. on April 1, 2026. Prescriptions were accepted immediately through LillyDirect, shipping began April 6, and broader availability through retail pharmacies and telehealth providers started April 9 ^[2]. The IQVIA figure covers the week ended April 10 and is likely based on only two days of captured data, analysts said ^[1][2].

For comparison, Novo Nordisk's oral Wegovy (semaglutide) recorded 3,071 U.S. prescriptions in the first four days after its January 5 launch ^[2], roughly three months ahead of Foundayo. In the same week Foundayo logged 1,390 prescriptions, oral Wegovy was prescribed 113,354 times, up from 105,366 the week before, according to IQVIA data ^[2].

Analysts cautioned against reading too much into the first week. "We think Foundayo's initial scripts look excellent," Jefferies analyst Akash Tewari said ^[2]. RBC Capital Markets analyst Trung Huynh said comparing the two launches now will not show which drug is more popular, and that weeks eight through twelve "represent the earliest window to assess Foundayo's true commercial momentum" ^[2]. Lilly told Reuters the early weekly figures "would not be fully comprehensive and may not capture the full breadth of pharmacy partners" and were "best interpreted over time rather than as a complete count" ^[2].

J.P. Morgan analyst Chris Schott said the oral Wegovy launch "is off to a solid start" and that the market appears to be expanding rather than pulling patients away from Lilly's Zepbound injection, which leads sales among weight-loss drugs ^[2]. Lilly shares rose more than 2% on Friday, April 17 ^[2]; an earlier report said the stock rose 1.6% before markets opened that day ^[1]. Lilly CEO David Ricks said the pills offer convenience, including for people who want to "graduate" from injectables after reaching their weight-loss goals, and said, "We can now provide a single-acting GLP-1, not as good as Zepbound or Mounjaro, but can meet the needs of a lot of people" ^[2].

The Food and Drug Administration approved Foundayo but still required post-approval safety studies, saying it could not fully characterize risks including heart attack, stroke, drug-induced liver injury and delayed stomach emptying from existing data ^[1]. The agency also asked for 15 years of thyroid cancer risk data, consistent with warnings on Wegovy and Zepbound, plus a registry tracking children and pregnant women who take the drug for obesity ^[1]. Thomas Seck, MD, Lilly's senior vice president of product development for cardiometabolic health, said: "Across seven Phase 3 studies enrolling more than 11,000 patients, Foundayo has demonstrated a consistent safety and efficacy profile" ^[1].

Why it matters for patients

Adults deciding between treatments now have a once-daily oral GLP-1 option approved for obesity that, according to Lilly, requires no food or water restrictions ^[1]. That is a practical difference from older oral semaglutide, which has dosing rules about when to take it. Whether insurers will cover Foundayo, and what patients will pay, has not been reported in these accounts; the reports describe drugmakers generally shifting toward cash-pay consumer models ^[2]. The launch-week counts also say nothing about how well the drug works for any one person, and the FDA's list of follow-up requirements shows some risks remain incompletely understood ^[1]. Foundayo is not approved for type 2 diabetes; Lilly is seeking that use ^[1].

What happens next

Lilly plans to submit Foundayo for approval to treat type 2 diabetes by the end of the second quarter of 2026, using a Commissioner's National Priority Review Voucher ^[1]. Analysts have pointed to eight to twelve weeks after launch as the first meaningful read on demand, but no specific date for that comparison has been announced ^[1][2]. Separately, the FDA-required follow-up work includes 15 years of thyroid cancer monitoring and registries for children and pregnant women treated for obesity ^[1].